Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL.

Ther Adv Hematol · 2019 · PMC6535706 · PMID 31205643

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

16 It has highly significant activity as a single agent in CLL as demonstrated in preclinical and early phase I studies. 17 Rituximab is a humanized murine monoclonal antibody targeting CD20 on mature B lymphocytes.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.